Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

VX-787 is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. Viral genetics and X-ray crystallography studies provide support for the idea that VX-787 occupies the 7-methyl GTP (m(7)GTP) cap-binding site of PB2. VX-7...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Byrn, Randal A., Jones, Steven M., Bennett, Hamilton B., Bral, Chris, Clark, Michael P., Jacobs, Marc D., Kwong, Ann D., Ledeboer, Mark W., Leeman, Joshua R., McNeil, Colleen F., Murcko, Mark A., Nezami, Azin, Perola, Emanuele, Rijnbrand, Rene, Saxena, Kumkum, Tsai, Alice W., Zhou, Yi, Charifson, Paul S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2015
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4325764/
https://ncbi.nlm.nih.gov/pubmed/25547360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04623-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados